Preparation method of paricalcitol

Abstract

The invention relates to a preparation method of paricalcitol, which is characterized in that after hydroxyl in the vitamin D2 is protected by p-toluenesulfonates, in the presence of alkali, intramolecular cyclization reaction happens in methanol to generate a compound 5; the compound 5 undergoes allylic oxidation and hydroxyl is protected to obtain a key intermediate 7; in the presence of ozone,the side chains and exocyclic terminal double bonds of the key intermediate 7 are cut off to obtain a compound 8; the primary hydroxyl in the compound 8 is selectively protected, a three-membered ring is opened in the presence of acid and then hydroxyl is protected to obtain a key intermediate 11; after the secondary hydroxyl in the key intermediate 11 is protected by sulphonate, a compound 12 isobtained through reduction by LiAlH4; a compound 13 is obtained after the compound 12 is subjected to Swern oxidation and carries out Wittig reaction with the compound 12 to obtain a compound 14; andthe target compound can be obtained by removing the protective group in the compound 14. The reagents used in the method are simple and are convenient to operate, the reactions concerning regioselectivity and stereoselectivity are few, the route is shorter and 12 steps of reactions are carried out.

Description

The preparation method of paricalcitol technical field The present invention relates to the synthesis of a compound, in particular to a preparation method of paricalcitol. Background technique Paricalcitol (active vitamin D treatment drug, Paricalcitol) is a drug for the prevention and treatment of secondary hyperparathyroidism (SHPT), which is effective for stage III and IV chronic kidney disease before dialysis and transplantation. SHPT in patients with CKD has shown preventive and therapeutic effects, and has become the most widely used drug for the prevention and treatment of SHPT in patients with dialysis. Serum phosphorus levels had minimal impact, and PTH reduction was a key indicator of efficacy of SHPT treatment. The binding of paricalcitol See formula 1 for construction: 1 Paricalcitol formula 1 Synthetic Paricalcitol mainly contains the following two methods in the prior art: The first route (US5281731, US5086191) adopts the strategy of converging to ca...

AI Technical Summary

Problems solved by technology

The second route is longer (WO2008053961, JP053392300), with more than seventeen steps

Among them, the Julia coupling olefination yield used when connecting the side chain is low, and the use of Na-Hg is not en

Images